Drugs / RBV
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01770223 Background | Jan 2014 → Dec 2015 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01770223 ↗ |
| Route | Oral | “RBV capsules orally, at a weight-based dose between 800-1400 mg/day divided into two daily doses” NCT01770223 ↗ |